3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
13
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
von Hippel-Lindau Disease
3
Pheochromocytoma
1
Paraganglioma
1
Kidney Neoplasms
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
pembrolizumab
16
Cisplatin
16
Magnetic Resonance Spectroscopy
13
Specimen Handling
12
Carboplatin
11
Paclitaxel
9
Platinum
8
1,2-diaminocyclohexaneplatinum II citrate
8
durvalumab
6
Radiotherapy, Intensity-Modulated
6
Pemetrexed
6
Cetuximab
6
cemiplimab
5
Radiotherapy
5
Radiation
5
Nivolumab
5
Biopsy
5
Ipilimumab
4
Fluorouracil
4
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
4
(225)Ac-DOTA-c(RGDyK)
4
poly ICLC
3
osimertinib
3
atezolizumab
3
Taxes
3
Oxaliplatin
3
Docetaxel
3
130-nm albumin-bound paclitaxel
3
ipatasertib
2
fludarabine phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
belzutifan
×
90 days
×
Clear all
NCT07227402
2026-06-04
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3
Recruiting
904 enrolled